已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

医学 安慰剂 兴奋剂 胰高血糖素样肽1受体 利拉鲁肽 胰高血糖素样肽-1 双盲 内科学 糖尿病 药理学 内分泌学 2型糖尿病 受体 替代医学 病理
作者
Carel W. le Roux,Oren Steen,Kathryn Jean Lucas,Elena Startseva,Anna Unseld,Anita M. Hennige
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:12 (3): 162-173 被引量:81
标识
DOI:10.1016/s2213-8587(23)00356-x
摘要

Summary

Background

Obesity is a widespread and chronic condition that requires long-term management; research into additional targets to improve treatment outcomes remains a priority. This study aimed to investigate the safety, tolerability, and efficacy of glucagon receptor–GLP-1 receptor dual agonist survodutide (BI 456906) in obesity management.

Methods

In this randomised, double-blind, placebo-controlled, dose-finding phase 2 trial conducted in 43 centres in 12 countries, we enrolled participants (aged 18–75 years, BMI ≥27 kg/m2, without diabetes) and randomly assigned them by interactive response technology (1:1:1:1:1; stratified by sex) to subcutaneous survodutide (0·6, 2·4, 3·6, or 4·8 mg) or placebo once-weekly for 46 weeks (20 weeks dose escalation; 26 weeks dose maintenance). The primary endpoint was the percentage change in bodyweight from baseline to week 46. Primary analysis included the modified intention-to-treat population (defined as all randomly assigned patients who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint) and was based on the dose assigned at randomisation (planned treatment), including all data censored for COVID-19-related discontinuations; the sensitivity analysis was based on the actual dose received during maintenance phase (actual treatment) and included on-treatment data. Safety analysis included all participants who received at least one dose of study drug. The trial is registered with ClinicalTrials.gov (NCT04667377) and EudraCT (2020–002479–37).

Findings

Between March 30, 2021, and Nov 11, 2021, we enrolled 387 participants; 386 (100%) participants were treated (0·6 mg, n=77; 2·4 mg, n=78; 3·6 mg, n=77; 4·8 mg, n=77; placebo n=77) and 233 (60·4%) of 386 completed the 46-week treatment period (187 [61%] of 309 receiving survodutide; 46 [60%] of 77 receiving placebo). When analysed according to planned treatment, mean (95% CI) changes in bodyweight from baseline to week 46 were −6·2% (−8·3 to −4·1; 0·6 mg); −12·5% (−14·5 to −10·5; 2·4 mg); −13·2% (−15·3 to −11·2; 3·6 mg); −14·9% (−16·9 to −13·0; 4·8 mg); −2·8% (−4·9 to −0·7; placebo). Adverse events occurred in 281 (91%) of 309 survodutide recipients and 58 (75%) of 77 placebo recipients; these were primarily gastrointestinal in 232 (75%) of 309 survodutide recipients and 32 (42%) of 77 placebo recipients.

Interpretation

All tested survodutide doses were tolerated, and dose-dependently reduced bodyweight.

Funding

Boehringer Ingelheim.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小姚姚完成签到,获得积分10
1秒前
5秒前
SYanan完成签到 ,获得积分10
8秒前
苹果树下的懒洋洋完成签到 ,获得积分10
8秒前
8秒前
斯文败类应助科研小白采纳,获得10
11秒前
12秒前
严明完成签到,获得积分10
12秒前
严明完成签到,获得积分10
13秒前
卧镁铀钳完成签到 ,获得积分10
15秒前
16秒前
小胖完成签到 ,获得积分10
17秒前
小二郎应助zhouleiwang采纳,获得10
17秒前
momo应助蓝天白云采纳,获得10
17秒前
尊敬代亦完成签到,获得积分10
18秒前
科研小白完成签到,获得积分10
19秒前
19秒前
在水一方应助科研通管家采纳,获得10
22秒前
bkagyin应助科研通管家采纳,获得10
22秒前
上官若男应助科研通管家采纳,获得10
22秒前
科研通AI2S应助科研通管家采纳,获得10
22秒前
22秒前
酷波er应助科研通管家采纳,获得10
22秒前
1111完成签到,获得积分10
22秒前
尊敬代亦发布了新的文献求助30
24秒前
gtgyh完成签到 ,获得积分10
24秒前
CodeCraft应助锦七采纳,获得10
24秒前
orixero应助www采纳,获得10
26秒前
27秒前
小真白发布了新的文献求助10
27秒前
Ancy完成签到 ,获得积分10
28秒前
不与仙同完成签到 ,获得积分10
28秒前
xx完成签到 ,获得积分10
29秒前
土豆完成签到,获得积分10
29秒前
tff完成签到 ,获得积分10
31秒前
32秒前
XU发布了新的文献求助10
33秒前
关关难过关关过完成签到,获得积分10
35秒前
碗在水中央完成签到 ,获得积分0
36秒前
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989957
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11255966
捐赠科研通 3270856
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882252
科研通“疑难数据库(出版商)”最低求助积分说明 809216